Loading stock data…
REGENXBIO Inc. (RGNX)
$9.73-0.52 (-5.07%)
Market ClosedLast close Jul 24
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
REGENXBIO Inc. in the Healthcare sector is trading at $9.73 with a market capitalization of $346M. Wall Street consensus targets $24.27 (11 analysts), implying a +149.5% move over the next 12 months. The stock is currently 40% below its 52-week high of $16.19, remaining 8.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +149.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.39M↓ | $30.34M↑ | $29.73M↑ | $21.36M↓ | $89.01M |
| Gross Profit | -$4.68M↓ | $24.41M↑ | $24.01M↑ | $16.15M↓ | $85.58M |
| Operating Income | -$83.36M↓ | -$57.64M↓ | -$52.41M↑ | -$63.28M↓ | $12.13M |
| Net Income | -$90.05M↓ | -$67.15M↓ | -$61.94M↑ | -$70.87M↓ | $6.08M |
Peer Comparison
JNJUNHPFE
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$345.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1375.64%
Volume
Today's trading volume
959,501
Recent News
New Strong Sell Stocks for July 23rd
ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff?
REGENXBIO plans to sell $100 million worth of its common stock in an underwritten public offering.
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
With a regulatory route now in place, Regenxbio expects to meet with the FDA again in July, with a BLA resubmission to follow in Q3 2026.